FDA grew too close to Biogen during Alzheimer’s drug development, doctors sayThe FDA got too close to Biogen during the development of the Alzheimer’s drug aducanumab, according to its Share XFDA grew too close to Biogen during Alzheimer’s drug development, doctors sayhttps://pharmaphorum.com/news/fda-grew-too-close-to-biogen-during-alzheimers-drug-development-doctors-say/
Biogen shares soar as FDA delays decision on aducanumabThe FDA has delayed its decision on aducanumab, the troubled Alzheimer’s drug from Biogen and Eisai by three Share XBiogen shares soar as FDA delays decision on aducanumabhttps://pharmaphorum.com/news/biogen-shares-soar-as-fda-delays-decision-on-aducanumab/
Could Lilly’s donanemab readout in Alzheimer’s boost Biogen’s prospects?When Eli Lilly reported results for donanemab in Alzheimer’s disease earlier this week it was hailed as a Share XCould Lilly’s donanemab readout in Alzheimer’s boost Biogen’s prospects?https://pharmaphorum.com/news/could-lillys-alzheimers-drug-readout-boost-biogens-prospects/
FDA panel unimpressed with data for Alzheimer’s drug aducanumabThe FDA may have been minded to approve Biogen and Eisai’s Alzheimer’s candidate aducanumab, but its clinical advisors Share XFDA panel unimpressed with data for Alzheimer’s drug aducanumabhttps://pharmaphorum.com/news/fda-sceptical-on-biogen-eisai-data-for-alzheimers-drug-aducanumab/
Trials and tribulations in Biogen’s Alzheimer’s drug reviewsRegulatory reviews of Biogen’s Alzheimer’s drug aducanumab are now ongoing on both sides of the Atlantic, but debate Share XTrials and tribulations in Biogen’s Alzheimer’s drug reviewshttps://pharmaphorum.com/news/trials-and-tribulations-in-biogens-alzheimers-drug-reviews/
Biogen’s shares surge again as FDA hurries Alzheimer’s drug reviewBiogen’s Alzheimer’s drug aducanumab could be on the market in the next few months after the FDA accepted Share XBiogen’s shares surge again as FDA hurries Alzheimer’s drug reviewhttps://pharmaphorum.com/news/biogens-shares-surge-again-as-fda-hurries-alzheimers-drug-review/
Biogen and Eisai trial drug in asymptomatic Alzheimer’s diseaseBiogen and Eisai have begun a new phase 3 study testing an Alzheimer’s antibody drug aimed at patients without symptoms but Share XBiogen and Eisai trial drug in asymptomatic Alzheimer’s diseasehttps://pharmaphorum.com/news/biogen-and-eisai-trial-drug-in-asymptomatic-alzheimers-disease/
Biogen shares pop as it completes filing for Alzheimer’s drug aducanumabBiogen’s share price was up sharply on Wednesday after the big pharma completed its filing of its Alzheimer’s Share XBiogen shares pop as it completes filing for Alzheimer’s drug aducanumabhttps://pharmaphorum.com/news/biogen-shares-pop-as-it-completes-filing-for-alzheimers-drug-aducanumab/
FDA clears US trials of Green Valley’s Alzheimer’s drugChina’s Shanghai Green Valley Pharmaceuticals has clearance to begin a late stage clinical trial to support a US filing Share XFDA clears US trials of Green Valley’s Alzheimer’s drughttps://pharmaphorum.com/news/fda-clears-us-trials-of-green-valleys-of-alzheimers-drug/
